Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

GlaxoSmithKline is diving deeper into the realm of synthetic lethality through a new partnership with Bay Area-based IDEAYA Biosciences. The two companies are exploring potential oncology treatments with emerging technology.

Pharmaceutical companies are no strangers to digital technology, either in the science that creates their products or in the business of bringing them to the people who prescribe them. As the use of digital-first experiences intensifies and the pharmaceutical industry is forced to evolve, companies will need to lean on their data and technologies in their engagement efforts to deliver elevated human experiences.

The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

GlaxoSmithKline inked deals earlier this year to support the development of multiple adjuvanted COVID-19 vaccine candidates and has now pledged to manufacture 1 billion doses of that efficacy-boosting system by 2021.

A group of tech companies is working on a patch about the size of a small bandage that could be worn to monitor for the elevated body temperatures that can sometimes signal the onset of COVID-19.

Waltham, Massachusetts-based biotech firm Skyhawk Therapeutics is expanding a strategic collaboration deal with Merck as the two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.

Repertoire Immune Medicines officially launched following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases.

CURE Pharmaceutical, an innovative drug delivery and development company, signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.

In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though. What may be more effective in the long run, is hitting a disease along multiple target lines. That is the idea at Cambridge, Mass.-based Immuneering.